Generic azacitidine approved in Canada

Micrograph showing
acute myeloid leukemia
Health Canada has approved Dr. Reddy’s Laboratories Ltd.’s Azacitidine for Injection 100 mg/vial, a bioequivalent generic version of VIDAZA® (azacitidine for injection). The generic drug is approved for the same indications as VIDAZA®. This includes treating adults with intermediate-2 or high-risk myelodysplastic syndromes (according to the International Prognostic Scoring System) who are not eligible for hematopoietic stem cell transplant. [Read Article]

Restrictive transfusion method safe in cardiac surgery patients

Blood for transfusion
Photo by Elise Amendola
Results of a large study suggest a restrictive transfusion strategy is safe for moderate- to high-risk patients undergoing cardiac surgery. Researchers found that patients had similar rates of various outcomes—death from any cause, myocardial infarction, stroke, or new-onset renal failure with dialysis—whether they received red blood cell (RBC) transfusions according to a restrictive strategy or a liberal one. C. David Mazer, MD, of St. Michael’s Hospital in Toronto, Ontario, Canada, presented these results at the American Heart Association’s Scientific Sessions 2017. [Read Article]

Antibody prevents GVHD in mice

Lab mice
Photo by Aaron Logan
Preclinical research suggests PRO 140, a humanized anti-CCR5 monoclonal antibody, can prevent graft-versus-host disease (GVHD) in mice. Mice that received 2 mg of PRO 140 twice weekly showed no signs of GVHD throughout the study period. On the other hand, all control mice exhibited signs of GVHD, starting 25 days after engraftment, and had to be sacrificed early. Researchers reported these results in Biology of Blood and Marrow Transplantation. [Read Article]